drugset

drugset / Trial / NCT04017546

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS

NCT04017546 ↗

Phase 1 Completed 14 enrolled Cyclacel Pharmaceuticals, Inc.

NaSingle-groupOpen-labelTreatment

Summary

A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory AML or MDS

Timeline

Start: 2019-08-02
Primary completion: 2022-11-15
Completion: 2023-04-05

Publications

Frame S, Saladino C, MacKay C, Atrash B, Sheldrake P, McDonald E, Clarke PA, Workman P, Blake D, Zheleva D. Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer. PLoS One. 2020 Jul 9;15(7):e0234103. doi: 10.1371/journal.pone.0234103. eCollection 2020.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CYC065	Small molecule	—	Intravenous
Background	Venetoclax	Small molecule	—	Oral

Indications